The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2020 | The current treatment landscape for AML
Christoph Röllig, MD, MSc, Dresden University of Technology, Dresden, Germany, discusses the latest advancements in the treatment of acute myeloid leukemia (AML). Successful novel agents with varying mechanisms of action are increasingly making their way into clinical practice. Venetoclax is an exciting agent currently used in several different combinations in AML. Tyrosine kinase inhibitors and immunotherapies are also areas of interest in AML. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
